DNDN News Alert Dendreon Corp (DNDN) 0.13 02/13/2015 22:29:4

New Post Public Reply Private Reply Replies (0) Message Board

Feb 13, 2015 at 11:29 PM

Dendreon Corp (DNDN) 0.13 $DNDN

Biotech-Twitter 2014: A Look Back at the Biotech Year Through the Twitter Lens
at The Street - Mon Dec 29, 5:00AM CST
Another crazy and profitable year in biotech investing was captured 140 characters at a time.
BLUE: 90.70 (+0.93), NWBO: 6.07 (+0.13), GILD: 101.90 (+1.10), DNDN: 0.13 (-0.02), ICPT: 209.12 (+7.12), JUNO: 40.52 (+0.18), GALE: 1.68 (+0.06), AGIO: 118.55 (+0.11), AEGR: 25.15 (+0.88), ABBV: 58.05 (+1.00), BMY: 60.04 (+0.56), MNKD: 7.00 (+0.02), CELG: 115.88 (+0.16)

Where Are They Now? A Look Back at the Best & Worst Biotech CEOs
at The Street - Tue Dec 16, 10:20AM CST
One biotech CEO won accolades in 2010 only to be razzed for poor performance in 2011.
VRTX: 113.66 (+4.03), MYGN: 34.03 (+0.40), DNDN: 0.13 (-0.02), CTIC: 2.23 (-0.02), REGN: 402.40 (+0.66), CELG: 115.88 (+0.16)

Nominees for Absolute Worst Bio-Technology CEOs of 2014 Are ...
at The Street - Mon Dec 15, 10:49AM CST
The CEOs of Aegerion, Dendron, CytRx, Galena, Repros, Northwest Bio and Retrophin deserve jeers for their performances this year, but who's the worst of the bunch?
NWBO: 6.07 (+0.13), DNDN: 0.13 (-0.02), RTRX: 13.92 (+0.44), CYTR: 2.96 (+0.23), RPRX: 8.76 (+0.09), GALE: 1.68 (+0.06), AEGR: 25.15 (+0.88)

Using Re-Engineered Immune Cells to Kill Leukemia Induces Lasting Remissions
at The Street - Sat Dec 06, 12:00PM CST
A new form of cancer immunotherapy known as CAR-T promises to radically change the way certain blood cancers are treated.
BLUE: 90.70 (+0.93), KITE: 62.59 (+0.82), DNDN: 0.13 (-0.02), NVS: 102.20 (-0.17), CELG: 115.88 (+0.16)

A New Combined Approach to Cancer Immunotherapy is Needed
ACCESSWIRE - Mon Dec 01, 11:35AM CST
NEW YORK, NY / ACCESSWIRE / December 1, 2014 / With the recent bankruptcy of Dendreon Corporation (NASDAQ

NDN) due to disappointing sales of its flagship Provenge prostate cancer vaccine, the future of cancer immunotherapy just got a bit cloudier. While Provenge itself will survive, Dendreon may end up going private in a debt restructuring deal.
DNDN: 0.13 (-0.02), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56)

Northwest Biotherapeutics' DCVax-L: A Reimbursement Perspective
Ryan Pawell - at Seeking Alpha - Sun Nov 23, 3:41AM CST

NWBO: 6.07 (+0.13), DNDN: 0.13 (-0.02)

Most active Nasdaq-traded stocks
AP - Tue Nov 18, 5:03PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
SPLS: 16.86 (-0.22), GILD: 101.90 (+1.10), FB: 75.74 (-0.49), DNDN: 0.13 (-0.02), MSFT: 43.87 (+0.78), INTC: 34.36 (+0.23), GRPN: 7.97 (+0.51), AAPL: 127.08 (+0.62), CSCO: 29.43 (-0.03)

Will Patterson Companies (PDCO) Surprise Earnings in Q2? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 4:40PM CST
Patterson Companies (PDCO) had a mixed first quarter in which revenues beat the Zacks Consensus Estimate while adjusted earnings fell shy.
KR: 72.86 (+0.41), DNDN: 0.13 (-0.02), BBY: 39.11 (-0.08), PDCO: 50.65 (-0.16)

Market Maker Surveillance Report. DNDN, YHOO, CRDC, FNMAS, SLTD, BABA, Highest Net Sell Volume and Negative Price Friction For Thursday, November 13th 2014
M2 - Fri Nov 14, 3:02AM CST
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Thursday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Thursday there were 4759 companies with "abnormal" market making, 1814 companies with positive Friction Factors and 3114 companies with negative Friction Factors. Here is a list of the top companies with the highest net sell volume on Thursday and lowest negative price Friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. Dendreon Corp (NASDAQ

NDN), Yahoo! Inc (NASDAQ:YHOO), Cardica Inc (NASDAQ:CRDC), Federal National Mortgage Association Fannie Mae (OTC:FNMAS), Solar3D Inc (OTC:SLTD), (NYSE:BABA). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
YHOO: 44.42 (+0.50), DNDN: 0.13 (-0.02), CRDC: 0.58 (+0.03), BABA: 89.05 (+1.95)

Political Intelligence Rules Urged On D.C. Insiders
at Investor's Business Daily - Thu Nov 13, 5:54PM CST
The term "political intelligence" may sound like an oxymoron, but it can make a difference in investors' portfolios and has drawn the eye of legislators and investigators. Political intelligence is the business of people providing information about...
DNDN: 0.13 (-0.02), UNH: 109.44 (-0.40), AET: 96.12 (-0.96), HUM: 152.67 (-1.06)

Biotech Stock Roundup: Gilead, AbbVie Score at Liver Meeting, Dendreon Files for Bankruptcy - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Nov 12, 7:48AM CST
Companies like AbbVie (ABBV), Gilead (GILD) and Achillion (ACHN) had a strong presence at the annual Liver Meeting.
VRTX: 113.66 (+4.03), GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), DNDN: 0.13 (-0.02), AMGN: 153.48 (+0.30), ABBV: 58.05 (+1.00), REGN: 402.40 (+0.66)

Earnings Forecast Recap for Alibaba, Apple, Zynga, Gilead Sciences, Dendreon, and Juniper
PR Newswire - Wed Nov 12, 7:45AM CST
EarningForecast.com has issued six earnings forecast research reports with special focus on financial performance of the following stocks: Alibaba (NYSE:BABA), Apple (NASDAQ:AAPL), Zynga (NASDAQ:ZNGA), Gilead Sciences (NASDAQ:GILD), Dendreon (NASDAQ

NDN), and Juniper (NYSE:JNPR).
GILD: 101.90 (+1.10), DNDN: 0.13 (-0.02), ZNGA: 2.24 (-0.42), AAPL: 127.08 (+0.62), JNPR: 23.84 (+0.19), BABA: 89.05 (+1.95)

Nasdaq stocks posting largest volume increases
AP - Tue Nov 11, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
HEAR: 2.54 (-0.14), LSBK: 13.50 (+0.24), VSAR: 18.04 (-0.55), SANW: 4.80 (+0.19), URRE: 1.75 (+0.01), EDUC: 4.18 (-0.13), MCEP: 6.29 (+0.12), CYAN: 8.72 (+0.13), DNDN: 0.13 (-0.02), SUMR: 2.91 (+0.02), CRTN: 3.62 (-0.11)

Dendreon Shares Plummet After It Files for Bankruptcy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 3:45PM CST
Dendreon filed voluntary petitions under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware.
MDVN: 104.71 (+0.67), AGN: 229.49 (+1.87), JNJ: 99.62 (+1.18), DNDN: 0.13 (-0.02)

Update: Dendreon Bankruptcy
Alexander Maxwell - at Seeking Alpha - Tue Nov 11, 12:55PM CST

DNDN: 0.13 (-0.02)

Clarification: Dendreon-Chapter 11 Filing story
By The Associated Press - AP - Tue Nov 11, 12:43PM CST
In a story Nov. 10, The Associated Press reported that Bank of New York Mellon was listed as the largest creditor in a Chapter 11 bankruptcy court filing involving the drugmaker Dendreon Corp. BNY Mellon administers $620 million in notes for investors; it does not own them.
DNDN: 0.13 (-0.02)

Bankruptcies, Breakouts, and Busts; What's Happening in Biotech?
ACCESSWIRE - Tue Nov 11, 10:34AM CST
CORAL GABLES, FL / ACCESSWIRE / November 11, 2014 / From prostate cancer drugs to stem-cell therapy, the biotech industry seems to encompass a variety of unique and innovative companies. According to market research firm IBISWorld, the global revenue of the Biotech industry is nearly $300 billion. Statista reports that more that $50Billion of US biopharmaceutical goods are exported and the industry is on pace to grow at a compounded annual rate of nearly 11%. IBIS notes that many small companies, alongside a few industry giants in pharmaceutical, chemical and agricultural firms, populate the global biotech industry. There is also a lower level of market share concentration as noted by IBISWorld estimates that the top four industry players will account for less than 28% of the industry's revenue in 2014. With so much potential there are certainly companies in the market, which have progressed to the next level and others that have mismanaged their businesses into bankruptcy.
DNDN: 0.13 (-0.02)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Navigating AI Laws: A New Era for Privacy & Security

Crucial Insights from the Convergence Conference Rich with intrigue, the privacy and AI governance game just upped its stakes. If there ever was a time to listen closely, it's now, people. With over 150 laws sprouting up faster than weeds, businesses are getting squeezed to keep their artificial ducks in a row. Last month over in New York, some big names in law and...

Chemours Faces Investor Fraud Suit: Action Needed Now

A Messy Situation Unfolds for Chemours Company You know, stumbling upon a battle scene like this isn't something I enjoy, but here we have Chemours Company (NYSE: CC) embroiled in a securities fraud lawsuit. It's like catching wind of a brawl outside your favorite tavern—can't ignore it, can you? The Lawsuit's Crux and Key Dates to Watch Here's the rundown. The fight...

CorePower Yoga Expands in Miami with New Studios

Greasing the Wheels of Miami's Wellness Scene If you're living under a rock, you might not have noticed, but CorePower Yoga is making some serious moves in Miami. We're talking about two new studios opening their doors: one in Midtown Miami, already rolling out the mats as of October 19, and another flagship joint soon to hit Coral Gables. Clearly, they see the demand for...

National Showrooms Expands into Virginia with Key Buy

A New Chapter for Greenwich Kitchens I'll tell you what's catching my eye this time—National Kitchen & Bath Showrooms are making their move into Virginia by snapping up Greenwich Kitchens, a well-regarded name in the local kitchen and bath scene. Founded back in '78, Greenwich Kitchens has been a staple in the Virginia Beach and Hampton Roads areas for nearly half a...

PrePass Intelligence: A Game-Changer for Fleets

Picture this: you're at the wheel of a beastly 18-wheeler, barreling down the highway and skipping weigh stations thanks to PrePass. But here’s where the real magic kicks in. PrePass Intelligence just rolled out, aiming to squeeze every last drop of value from bypass and toll data. That's cold hard cash for fleet operators who can finally make sense of these fleeting...

Roof Inspections: Richmond's Key to Home Longevity

Inspect, Protect, and Forget Your Worries Homeowners in the Greater Richmond area wisely take to heart the old saying: an ounce of prevention is worth a pound of cure. But let's cut through the noise for a moment and zero in on a foundational truth: regular roof inspections are not a luxury—they're an absolute must. Roofing expert Seth Brown, from BNH Roofing, makes it...

QFIN Faces Class Action: Investors' Role Explored

Cracks in the Facade: QFIN's Legal Mess You're cruising down the usual market lanes when—bam!—news breaks that Qfin Holdings, Inc. (NASDAQ: QFIN) finds itself hip-deep in a class action lawsuit. Seems like our pals at Schall, Brown & Schwartz LLP have thrown the gauntlet down, with claims of some serious smoke and mirrors during the March to August stretch of 2026....

Ford Foundation Welcomes Gender Justice Leader Fatima Goss Graves

A Fresh Addition to Ford's Trustees Fatima Goss Graves steps into big shoes at the Ford Foundation as she gets appointed to its Board of Trustees. No small potatoes, this move suggests the Foundation's commitment to driving significant gender justice and advocacy. Add her name next to serious change-makers, folks, because Ms. Goss Graves is a heavyweight in the nonprofit...

Tenet® Beef: Revolutionizing Tenderness in America's Steaks

Cracking the Code: A Genetic Leap in Beef Tenderness Well, buckle up, folks, because Callipyge Genetics is shaking things up in the beef aisle with their genomic breakthrough, Tenet®. It's about time we see some real innovation in an industry that's, let's face it, been slow to evolve. This isn't just a flash in the pan—a bit of DNA parsing has uncovered how to...

Moore Law Urges Millrose Investors: Join the Action

Is Millrose Playing a Risky Game? When I caught wind of this latest debacle with Millrose Properties, Inc. (NYSE: MRP), my gut reaction was a mix of curiosity and skepticism. Hunterbrook Media's report just blasted across the headlines, digging up some dirt on Millrose's recent financial maneuvers. Apparently, these cats have been busy buying homes to the tune of $200...